Abstract
Magnetic resonance spectroscopy (MRS) is a non-invasive method of exploring cerebral metabolism. In Huntington’s disease, altered MRS-determined concentrations of several metabolites have been described; however, findings are often discrepant and longitudinal studies of metabolite trajectory are lacking. MRS metabolites may represent a valuable source of biomarkers, thus their relationship with established biofluid and structural imaging markers of disease progression require further exploration to assess prognostic value and elucidate biochemical pathways associated with neurodegeneration. In a prospective single-site controlled cohort study with standardised collection of CSF, blood, phenotypic and imaging data, we used MRS to evaluate metabolic profiles in the putamen of 56 participants at baseline (15 healthy controls, 15 premanifest and 26 manifest gene expansion carriers) and at 2-year follow-up. Intergroup differences and associations with established measures were assessed cross-sectionally using generalized linear models and partial correlation, controlling for age and CAG repeat length. We report no significant groupwise differences in metabolite concentration but found several metabolites to be associated with measures of disease progression; however, only two relationships were replicated across both time points, with total Creatine (creatine + phosphocreatine) and myo-inositol displaying significant associations with reduced caudate volume. Although relationships were observed between MRS metabolites and biofluid measures, these were not consistent across time points. To further assess prognostic value of the metabolites, we examined whether baseline MRS values, or rate of change, predicted subsequent change in established measures of disease progression. Several associations were found but were inconsistent across known indicators of disease progression. Finally, longitudinal mixed effects models, controlling for age, revealed no significant change in metabolite concentration over time in gene expansion carriers. Altogether, our findings show some interesting cross-sectional associations between select metabolites, namely total creatine and myo-inositol, and markers of disease progression, potentially highlighting the proposed roles of neuroinflammation and metabolic dysfunction in disease pathogenesis. However, the absence of group differences, inconsistency between baseline and follow-up, and lack of clear longitudinal change over two years suggests that MRS metabolites have limited potential as biomarkers in Huntington’s disease.
Competing Interest Statement
AJL, FBR, LMB, EBJ, RIS, AH, HZ and EJW are University College London employees. RT is a full-time employee of F.Hoffmann-La Roche Ltd. MA is a University College London Hospitals NHS Foundation Thrust employee. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. LMB has provided consultancy services to GLG, F. Hoffmann-La Roche Ltd, Genentech, Novartis, Remix and Annexon Biosciences. RIS has undertaken consultancy services for Ixico Ltd. EJW reports grants from Medical Research Council (MRC), CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda, Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program
Funding Statement
This work was supported in part by the National Institute for Health Research University College London Hospitals Biomedical Research Centre, the UCL Leonard Wolfson Experimental Neurology Centre, and the Swedish Research Council. E.J.W. has research funding from the Medical Research Council UK (MR/M008592/1) (https://mrc.ukri.org/funding/), CHDI Foundation Inc (https://chdifoundation.org/) and European Huntingtons Disease Network (http://www.ehdn.org/). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimers Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2019-0228), the European Unions Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL (https://www.ucl.ac.uk/uk-dementia-research-institute/). LMB has research funding from Huntingtons disease Society of America, Hereditary disease foundation and F.Hoffmann-La Roche Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the London Camberwell St Giles Research Ethics Committee (15/LO/1917), with all participants providing written informed consent prior to enrolment. This study was performed in accordance with the principles of the Declaration of Helsinki, and the International Conference on Harmonization Good Clinical Practice standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, EJW. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
Abbreviations
- Cho
- choline
- Cr
- creatine
- CTR
- healthy controls
- cUHDRS
- composite Unified Huntington’s Disease Rating Scale
- DBS
- disease burden score
- DCL
- diagnostic confidence level
- Glu
- glutamate
- Glx
- glutamine + glutamate
- GSH
- Glutathione
- HD
- manifest mutation carriers
- Lac
- Lactate
- LLoQ
- lower limit of quantification
- LoD
- limit of detection
- mHTT
- mutant Huntingtin
- MI
- myo-inositol
- MRS
- magnetic resonance spectroscopy
- NfL
- neurofilament light chain
- PreHD
- premanifest mutation carriers
- PVE
- partial volume effect
- ROS
- reactive oxygen species.
- SD
- standard deviation
- SDMT
- Symbol Digit Modality Test
- SNR
- signal-to-noise ratio
- SWR
- Stroop Word Reading
- tCho
- total choline (phosphocholine + glycophosphocholine)
- tCre
- total creatine (creatine + phosphocreatine)
- TFC
- Total Functional Capacity
- TIV
- total intracranial volume
- TMS
- Total Motor Score
- tNAA
- total N-acetylaspartate (N-acetylaspartate + N-acetylaspartate-glutamate)
- VFC
- Verbal Fluency (Categorical)
